Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
The findings, published today in Cancer Discovery, were first presented at the American Association for Cancer Research...
Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly...
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy...
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
The overall response rate among 60 patients was 53%, and the rate of complete remission or complete...
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue...
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints...
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022...
ABSTRACTS 62, 82, 95, 199, 232, 540, 708, 766, 960
The University of Texas MD Anderson Cancer Center’s Research Highlights provides...
Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson...
ABSTRACTS GS1-07, GS5-08, PD6-11, HER2-01
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center and Exscientia plc today announced a strategic collaboration to align the drug discovery...
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
Nanotechnology platform enables immune conversion of cancer cells, sensitizing them to immunotherapy
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way...
ABSTRACTS: 374, 568, 590, 657, 659, 782
The University of Texas MD Anderson Cancer Center’s...
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco...
In recognition of her trailblazing work uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, Ph.D., chair of...
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe...
Patients with early-stage breast cancer who had a pathologic complete response (pCR) to neoadjuvant chemotherapy may be able to skip surgery...
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its internal advisory...
The University of Texas MD Anderson Cancer Center and World Health Organization (WHO) today announced a formal agreement to establish a new...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center will host its virtual Leading Edge of Cancer Research Symposium from November 17-18, 2022...
Three new cancer research projects have been chosen to receive seed funding as part of the program in Oncological Data and Computational Science...
The University of Texas MD Anderson Cancer Center and ARTIDIS AG today announced a strategic alliance to investigate ARTIDIS technology as...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to engineering natural killer (NK) cells with...
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific gut bacterium involved in the progression of graft-versus-host...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight...
The University of Texas MD Anderson Cancer Center was awarded $2.5 million today from the Cancer Prevention and Research Institute of Texas...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint...
Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating...
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in...
ABSTRACT 789O
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3%...
ABSTRACT 2170O
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2...
ABSTRACTS 735MO, 316O, 1MO, 1493MO, 457MO, 283MO, LBA68, 785O
The University of...
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development...
Swathi Arur, Ph.D., professor and deputy chair of Genetics at The University of Texas MD Anderson Cancer Center, has been selected as one...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center and Erasca, Inc. today announced a strategic research and development collaboration...
The University of Texas MD Anderson Cancer Center today was awarded $2.5 million in continued funding from the Cancer Prevention and Research...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its scientific advisory...
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. today announced an exclusive license and joint development...
The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
Cancer cells produce small amounts of their own form of collagen, creating a unique extracellular matrix that affects the tumor microbiome...
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (...
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased...
Donna Hansel, M.D., Ph.D., to join MD Anderson as Division Head of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center today announced that Donna Hansel, M.D., Ph.D., has been named Division Head of Pathology...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center today announced Kimberly Hoggatt Krumwiede, Ph.D., as dean of MD Anderson’s School of Health...
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development...
The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA levels...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
A new study led by the global Cancer Grand Challenges PRECISION team, including researchers from The University of Texas MD Anderson Cancer...
CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising...
ABSTRACTS: 2006, 2511
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of...
ABSTRACTS 7518, 7509, 8009
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being...
ABSTRACT: LBA11501
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses...
Eduardo Bruera, M.D., chair of Palliative Care Medicine at The University of Texas MD Anderson Cancer Center, has received...
ABSTRACT LBA7502
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free...
The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the Cell Therapy...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of...
The University of Texas MD Anderson Cancer Center today announced that Tong Joo (TJ) Gan, M.D., has been named Division Head of Anesthesiology...
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network today announced a partnership agreement...
The University of Texas MD Anderson Cancer Center was awarded more than $10 million in grants to support collaborative research teams working...
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Abstract: LB119
Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that...
NEW ORLEANS ― Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers — ATR inhibitor...
Abstract: CT003
Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The American Association for Cancer Research (AACR) has honored Lee Ellis, M.D., professor of Colon and Rectal Surgery at The University of...
The American Association for Cancer Research (AACR) has honored acclaimed investigator Karen Lu, M.D., chair of Gynecologic Oncology and Reproductive...
The University of Texas MD Anderson Cancer Center applauds the unanimous vote by Houston City Council today to amend the city’s ordinance...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that two distinct classes of cancer-associated fibroblasts...
The University of Texas MD Anderson Cancer Center today launched the James P. Allison Institute, a visionary research and innovation...
A multicenter research team co-led by The University of Texas MD Anderson Cancer Center developed the first drug to treat the uncontrolled...
Neal G. Copeland, Ph.D., and Nancy A. Jenkins, Ph.D., both professors of Genetics at The University of Texas MD Anderson Cancer Center...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
A new computational approach developed by researchers at The University of Texas MD Anderson Cancer Center successfully combines data from...
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new radio-labeled molecule capable of selectively reacting...
The University of Texas MD Anderson Cancer Center was awarded $31.73 million from the Cancer Prevention and Research Institute of Texas (CPRIT...
The University of Texas MD Anderson Cancer Center announced today its first-ever partnership renewal with Banner Health, which created Banner...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
The University of Texas MD Anderson Cancer Center celebrates World Cancer Day, Feb. 4, in honor of the global initiative to end cancer.
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
In honor of their notable contributions to the field of cancer research, Juan Fueyo, M.D., and Victor Prieto, M.D., Ph.D., from The University...
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology...
Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles...
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer...
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free...